174 related articles for article (PubMed ID: 17055256)
1. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.
Rakha EA; El-Rehim DA; Paish C; Green AR; Lee AH; Robertson JF; Blamey RW; Macmillan D; Ellis IO
Eur J Cancer; 2006 Dec; 42(18):3149-56. PubMed ID: 17055256
[TBL] [Abstract][Full Text] [Related]
2. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
3. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Cancer; 2009 Nov; 115(21):4917-23. PubMed ID: 19691094
[TBL] [Abstract][Full Text] [Related]
4. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
[TBL] [Abstract][Full Text] [Related]
5. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up.
Evans AJ; Rakha EA; Pinder SE; Green AR; Paish C; Ellis IO
J Med Screen; 2007; 14(4):210-4. PubMed ID: 18078567
[TBL] [Abstract][Full Text] [Related]
6. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
[TBL] [Abstract][Full Text] [Related]
8. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
9. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers.
Baak JP; Colpaert CG; van Diest PJ; Janssen E; van Diermen B; Albernaz E; Vermeulen PB; Van Marck EA
Eur J Cancer; 2005 Sep; 41(14):2093-101. PubMed ID: 16153819
[TBL] [Abstract][Full Text] [Related]
10. High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas.
Madjd Z; Parsons T; Watson NF; Spendlove I; Ellis I; Durrant LG
Breast Cancer Res; 2005; 7(5):R780-7. PubMed ID: 16168124
[TBL] [Abstract][Full Text] [Related]
11. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
[TBL] [Abstract][Full Text] [Related]
12. The influence of basal phenotype on the metastatic pattern of breast cancer.
Luck AA; Evans AJ; Green AR; Rakha EA; Paish C; Ellis IO
Clin Oncol (R Coll Radiol); 2008 Feb; 20(1):40-5. PubMed ID: 17981444
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumours.
Fiets WE; Bellot FE; Struikmans H; Blankenstein MA; Nortier JW
Eur J Surg Oncol; 2005 Mar; 31(2):128-33. PubMed ID: 15698727
[TBL] [Abstract][Full Text] [Related]
14. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer.
Dellas A; Torhorst J; Schultheiss E; Mihatsch MJ; Moch H
Clin Cancer Res; 2002 May; 8(5):1210-6. PubMed ID: 12006540
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin profiles of male breast cancers.
Ciocca V; Bombonati A; Gatalica Z; Di Pasquale M; Milos A; Ruiz-Orrico A; Dreher D; Folch N; Monzon F; Santeusanio G; Perou CM; Bernard PS; Palazzo JP
Histopathology; 2006 Oct; 49(4):365-70. PubMed ID: 16978199
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
[TBL] [Abstract][Full Text] [Related]
18. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Di Saverio S; Gutierrez J; Avisar E
Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
[TBL] [Abstract][Full Text] [Related]
19. Classification and grading of invasive breast carcinoma.
Elston CW
Verh Dtsch Ges Pathol; 2005; 89():35-44. PubMed ID: 18035670
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]